All In Biotech

Drug Trial Radar · NCT04594681

A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration

A Phase I Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: May 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 116 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

116

Actual

Start

Sep 16, 2020

Primary completion

Aug 26, 2022

Study completion Aug 26, 2022

Sponsor

Lead sponsor
Kyowa Kirin Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate safety and tolerability after administration of KHK4951 in healthy volunteers and patients with wet age-related macular degeneration.

Conditions

  • Healthy Volunteers
  • Wet Age-related Macular Degeneration

Interventions

  • PlaceboDrug

    Placebo is administered once daily or three times daily.

  • KHK4951Drug

    KHK4951 is administered once daily or three times daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse eventsTime frame: Day 1 to Day 43

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hakata clinic

    Fukuoka, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.